Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: Efforts have been initiated to define and grade cytokine release syndrome (CRS), to identify patients at risk, to describe biomarkers that predict onset and severity, to understand the pathophysiology, and to prevent and treat severe cases to reduce T cell immunotherapy-related morbidity and mortality. Optimizing the timing of T cell-based therapies in ALL, identifying new biomarkers, and investigating novel anti- cytokine agents that have anti-CRS activity are likely to be fruitful avenues of study.
|
Authors | Ibrahim Aldoss, Samer K Khaled, Elizabeth Budde, Anthony S Stein |
Journal | Current oncology reports
(Curr Oncol Rep)
Vol. 21
Issue 1
Pg. 4
(01 21 2019)
ISSN: 1534-6269 [Electronic] United States |
PMID | 30666425
(Publication Type: Journal Article, Review)
|
Chemical References |
|
Topics |
- Cytokine Release Syndrome
(etiology, physiopathology, therapy)
- Cytokines
(metabolism)
- Humans
- Immunotherapy
(adverse effects)
- Immunotherapy, Adoptive
(adverse effects)
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
(therapy)
|